Plexion (sulfacetamide-sulfur topical) is filed as Topical Anti-Acne. The sections below restate public label fields stored for this profile.
INDICATIONS: This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.
CLINICAL PHARMACOLOGY: Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive Gram-positive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. There is no clinical data available on the degree and rate of systemic absorption of this product when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported. The following in vitro data is available, but the clinical significance is unknown. Organisms that show susceptibility to sodium sulfacetamide are: Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardiaand Actinomyces. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.
Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN.
CONTRAINDICATIONS: This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.
Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).
DOSAGE AND ADMINISTRATION: Cleanse affected areas. Apply a thin layer to the affected areas with light massaging, 1 to 3 times daily or as directed by a physician.
According to its FDA label, Plexion (sulfacetamide-sulfur topical) is approved for: INDICATIONS: This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. For medical advice, please talk to your prescriber or pharmacist.
Plexion (sulfacetamide-sulfur topical) belongs to the Topical Anti-Acne class of medications.
The FDA label lists Plexion (sulfacetamide-sulfur topical) as: HOW SUPPLIED: 16 fl. oz. (473 mL) bottles, NDC 24470-950-16 To report a serious adverse event or obtain product information, call 1-855-899-4237. Manufactured for: Cintex Services, LLC Dallas, TX 75243 2500196 [00] Rev. 07/2025; topical route. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Plexion (sulfacetamide-sulfur topical) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Plexion (sulfacetamide-sulfur topical) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Plexion (sulfacetamide-sulfur topical) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA label lists Cintex Services, LLC as a labeler/manufacturer of Plexion (sulfacetamide-sulfur topical). Multiple firms may market generics of the same molecule.
The FDA label states: "STORAGE: Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…